Clinical efficacy and microbiota analysis of Xipayi mouth rinse combined with thalidomide tablets for the treatment of erosive oral lichen planus
Objective To observe the clinical efficacy and microbiome changes in patients with erosive oral lichen planus(E-OLP)treated with Xipayi mouth rinse in combination with thalidomide tablets.Methods Sixty patients with E-OLP who were diagnosed at Jiamusi University Affiliated Stomatological Hospital from September 2020 to July 2021 were enrolled in this study.Patients were randomly divided into an observation group and a control group,with 30 patients in each group.In addition to the standard treatment with thalidomide tablets,the control group received a mouth rinse with distilled water,while the observation group received a mouth rinse with Xipayi mouth rinse.Among the observation group,10 patients were randomly selected and divided into group A and group B based on the time points of 4 weeks before and after treatment.Mixed swabs of buccal mucosa and saliva were collected from both groups for high-throughput sequencing.Clinical efficacy was compared between the observation and control groups four weeks post-treatment.Additionally,improvements in oral health status(VAS score,REU score,OHIP-14 score)were compared before treatment and at 1 and 4 weeks post-treatment.Adverse events,as well as changes in oral microbiota between groups A and B,were also analyzed.Results The total effective rate in the observation group was 80.00％,significantly higher than that of the control group(53.33％)(x2=4.800,P=0.028).After treatment,both the REU and VAS scores,as well as the OHIP-14 score,decreased significantly in both the observation and control groups compared to baseline and the previous time point.Additionally,the observation group showed lower scores than the control group at the corresponding time points.The differences between the two groups at both 1 week and 4 weeks post-treatment were statistically significant(P＜0.05 or P＜0.01).Only one case(3.33％)of mild rash was observed in the control group,and no other adverse reactions were reported in the remaining patients.A total of 949 302 clean reads and 9 245 amplicon sequence variants(ASVs)with an average length of 426 bp were obtained from high-throughput sequencing of samples from groups A and B.Beta diversity analysis showed significant differences in the microbial community between the two groups(P＜0.05).Analysis of species composition revealed inter-group differences in the abundance of genera such as Fusobacterium,Rothia,and Filibacter,as well as phyla such as Bacteroidetes and TM7(P＜0.05).Conclusion Xipayi mouth rinse can modulate the oral microbiota in patients with E-OLP.The combination of Xipayi mouth rinse with traditional immunomodulatory drugs for the treatment of E-OLP can improve clinical efficacy,demonstrating a positive significance.
万方数据
维普
